ArticleCurrent microbiology2026
The Potential of MIC17A both as an Entero-epithelial and Chronic Stage Marker for Detection of Feline Toxoplasmosis.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxoplasma gondii is a zoonotic protozoan with significant clinical relevance. As the definitive host, felids are the key drivers of the parasite to intermediate hosts, including humans. Thus, early detection of infection in cats is critical to control toxoplasmosis. The micronemal protein MIC17A is a known marker of feline toxoplasmosis; however, its diagnostic performance in PCR-tested cases has not been evaluated. This study assessed 422 feline sera (56 RT-PCR positive, 366 RT-PCR negative) by indirect-ELISA (rMIC17A-based ELISA). The parasite seroprevalence was 41.9% by rMIC17A compared to tachyzoite lysate antigen (TLA)-based ELISA (37.2%). Based on both markers, the overall detection of feline toxoplasmosis increased to 54.7%. Of the 56 RT-PCR-positive samples, 50% and 42.8% were seropositive by the rMIC17A and TLA-based ELISAs, respectively, with an overall detection rate of 64.2%. Among the RT-PCR-negative 366 samples, 40.7% and 36.34% were seropositive according to the rMIC17A and TLA-based ELISAs, respectively. The detection rate increased to 53.27% once the outcome from both markers were considered. The higher seropositivity rate of the rMIC17A-based ELISA in PCR-positive cats suggests that naturally expressed MIC17A can induce IgG response earlier than tachyzoite antigens, which is consistent with its expression in the merozoite-primed presexual stage. Moreover, the diagnostic performance of rMIC17A is also detected higher in PCR-negative samples suggesting that it is also a late-stage infection marker consistent with its high transcript levels in bradyzoites. In conclusion, rMIC17A may represent both entero-epithelial (EES) and chronic-stage detection marker for feline toxoplasmosis and improve diagnostic accuracy when combined with conventional markers.
Indexed as
Identifiers
41874672What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.